GlassScriptPhysician profile
Tara Newman Smith
NPI 1093989733
$4,709.25
in general payments reported to CMS, 2019-2025
14 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $838 · 2023: $635 · 2024: $979 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Travel and Lodging: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.60 |
| Travel and Lodging | $493.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,365.71 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Livanova USA, INC. | $1,172.68 | 2021-2025 | Vns Therapy |
| Neurelis, INC. | $925.11 | 2022-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $448.12 | 2022-2025 | |
| Eisai INC. | $238.47 | 2021-2023 | |
| Catalyst Pharmaceuticals, INC. | $215.57 | 2023-2025 | Fycompa |
| Aquestive Therapeutics, INC. | $78.73 | 2022 | |
| Supernus Pharmaceuticals, INC. | $73.25 | 2021-2022 | |
| Immedica Pharma US, INC. | $68.10 | 2023-2024 | |
| Zogenix INC. | $38.12 | 2021 | |
| Biomarin Pharmaceutical INC. | $29.14 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $21.06 | 2024-2025 | Motpoly Xr |
| Janssen Pharmaceuticals, INC | $20.79 | 2024 | Spravato |
| Amneal Pharmaceuticals LLC | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.